Entries by Michael Kuhrt

Product hopping Boon or Bane?

Intellectual Property Providing access to medicines at affordable prices while maintaining incentives for the originators to invest into significant innovations is a balance that’s hard to find. Product hopping is a strategy for originators to minimise the erosion of their sales that has caught the attention of regulators and courts.

Product hopping – Boon or Bane?

Intellectual Property Providing access to medicines at affordable prices while maintaining incentives for the originators to invest into significant innovations is a balance that’s hard to find. Product hopping is a strategy for originators to minimise the erosion of their sales that has caught the attention of regulators and courts.

Expansion through partnerships

Immatics Biotechnologies has landed a potential US$1.1bn deal with GlaxoSmith­Kline (GSK) to find novel cancer targets on solid tumours and to direct TCR-T cell therapies against them. European Biotechnology spoke with Dr Harpreet Singh, CEO of Immatics Biotechnologies.

European assets ahead despite virus panic

Every year, it’s the same: in January, investors are scratching their heads, searching to find investment ideas that could ensure the greatest return/performance. Given the current valuation, can 2020 deliver windfall surprises for European names?